OBR Green Articles (ESMO / ECC Conference Coverage)

article

October 2019Edition

At ESMO 2019, the biggest clinical news was three late-stage standout studies in first-line advanced ovarian cancer with the PARP inhibitors niraparib, olaparib, and veliparib. Data from the three trials, PRIMA, PAOLA-1, and VELIA respectively, demo...

article

October 2019Edition

A round-up of some of the notable pivotal trial data presented in Barcelona that expanded treatment options for patients, including studies in triple negative breast cancer (KEYNOTE-522), advanced NSCLC (CheckMate 027), EGFR-mutation positive NSCLC (...

article

October 2019Edition

At Flatiron’s OncoCloud ’19 meeting, OBR sat down with three leading OneOncology providers to talk about how implementing data-connectivity through cloud-based oncology software like OncoEMR is changing the face of community oncology, delivery mo...

article

October 2019Edition

In another exclusive report, OnPoint Oncology provides an analysis of the largest non-Blue Commercial plans compared to the gold standard, Medicare. The analysis looks at the data on denial rates, days from service to claims filing (Days to File), an...